Burfiralimab Reference: HY-P99490 Burfiralimab (hzVSF-v13) is a monoclonal IgG4 antibody against vimentin expressed on the surface of virus-infected cells, with broad-spectrum antiviral activity and anti-inflammatory effects against virus-induced inflammation. Burfiralimab can be used in severe COVID-19 studies.
Nebacumab Reference: HY-P99751 Nebacumab (HA-1A) is a monoclonal antibody that binds to lipid A portion of endotoxin. Nebacumab can be used of research of sepsis.
Omfiloctocog alfa Reference: HY-P99769 Omfiloctocog alfa (SCT-800) is a recombinant factor VIII (FVIII). FVIII is an essential blood coagulation protein and a key component of the fluid phase blood coagulation system. Omfiloctocog alfa can be used for the research of Hemophilia A.
Panobacumab Reference: HY-P99214 Panobacumab (KBPA101) is a fully human IgM/κ monoclonal antibody generated by immortalizing human B lymphocytes against the LPS O polysaccharide of serotype O11 of P. aeruginosa.
Phospho ATF2 Antibody Panel (Total, pT69, pT71) Reference: ARG30227 Phospho ATF2 antibody; Phospho Activating transcription factor 2 antibody; ATF2 phospho (Thr69 or 51) antibody; ATF2 phospho (Thr71 or 53) antibody; ATF2 antibody
Ontamalimab Reference: HY-P99411 Ontamalimab (SHP647) is a fully-human IgG2 monoclonal antibody targeting mucosal addressin cell adhesion molecule-1 (MAdCAM-1). Ontamalimab can be used for the research of Crohn's disease.
Phospho Integrin beta 3 Antibody Panel (Total, pY773, pY785) Reference: ARG30230 Phospho Integrin beta 3 antibody; CD61 / Integrin beta 3 phospho (Tyr773) antibody; CD61 / Integrin beta 3 phospho (Tyr785) antibody; CD61 / Integrin beta 3 antibody (N-term)
Anbenitamab Reference: HY-P99437 Anbenitamab (KN-026) is a bispecific antibody simultaneously targeting the extracellular domains II and IV of the human HER2. Anbenitamab blocks both ligand-dependent and ligand-independent HER2 signaling pathway. The IgG1 Fc fragment of Anbenitamab binds FcRγIIIa mediates potent antibody dependent cell-mediated cytotoxicity (ADCC) and inhibits tumor cell proliferation. Anbenitamab has the potential for HER2-positive metastatic breast cancer (MBC) research.